Načítá se...
Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy
Hepatitis B virus (HBV) reactivation can lead to severe acute hepatic failure and death in patients with HBV infection. HBV reactivation (HBVr) most commonly develops in patients undergoing cancer chemotherapy, especially B cell-depleting agent therapy such as rituximab and ofatumumab for hematologi...
Uloženo v:
| Vydáno v: | World J Clin Cases |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Baishideng Publishing Group Inc
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8316946/ https://ncbi.nlm.nih.gov/pubmed/34368296 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12998/wjcc.v9.i21.5769 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|